Therapeutic Solutions International Recruits
Internationally Recognized Cancer Immunotherapy Pioneer Dr.
Francesco Marincola to Accelerate StemVacs and NanoStilbene
Clinical Development
Company Focuses on Non-Toxic Therapies Using Immune
System
to Selectively Kill Cancer Cells through Immunotherapy
Oceanside, CA -- July
23, 2018 -- InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced
the
appointment of Dr. Francesco Marincola to the Company's Scientific
Advisory Board. Dr. Marincola is currently Chief Science Officer at
Refuge Biotechnologies, Menlo Park, California. Most recently, he
served as a distinguished research fellow and strategist for immune
oncology discovery at AbbVie, Inc a 148 Billion
Dollar Market Cap Company.
Other notable
positions he held include leading programs at the Sidra Medical and
Research Center in Qatar and the National Institutes of Health. He
is currently leading worldwide efforts to understand the mechanism
of cancer immune resistance such as the Society for the
Immunotherapy of Cancer Task Force on Immune Responsiveness aimed
at involving different areas of expertise besides
immunology.
"We are very honored
to be joined by such a visionary and leader in the area of cancer
immunotherapy. Dr. Marincola was a believer and practitioner of
immunotherapy, decades before the "Golden Era of
Immunology" in which we
currently are in," said Timothy Dixon,
President and CEO of Therapeutic Solutions International. "Dr.
Marincola performed the initial work on tumor infiltrating
lymphocytes and interleukin-2 immunotherapy, which served as the
foundation for the numerous immunotherapeutic drugs that are
currently approved by the FDA including checkpoint inhibitors and
CAR-T cells."
Immunotherapy uses
the patient's own immune system to kill cancer cells. Currently the
FDA has approved two major classes of immunotherapy: 1. Checkpoint
inhibitors such as Ipilimumab, Nivolumab, Pembrolizumab,
Atezolizumab, Avelumab, and Durvalumab, act to "take the brakes
off" the immune system, resulting in immune hyperactivation and
tumor regression; and 2. CAR-T cells, such as Yescarta and Kymriah,
which are genetically engineered T cells programmed to selectively
kill cancer cells.
"Despite the
tremendous excitement of immunotherapy, the sad reality is that
only about 20% of patients have responses to checkpoint inhibitors,
and CAR-T cells are currently only applicable to
patients with blood
malignancies," said Dr. James
Veltmeyer, the Company's Chief Medical Officer. "We at Therapeutic
Solutions International are focusing on our StemVacs program, which
seeks to train T cells to kill cancer stem cells utilizing
dendritic cell technology, and NanoStilbene, a nutraceutical based
augmenter of immunotherapy for which we received US Patent
#9,682,047. We are excited to work with Dr. Marincola, one of the
first to utilize immunotherapy, in order to accelerate clinical
development of our approaches to cancer."
"While the concept of
using the immune system as cancer therapy is accepted, there is a
great need for novel approaches. I am excited to work with the
Company at developing StemVacs, a cell therapy product, and
NanoStilbene, an inexpensive, nanotechnology based nutraceutical
that has shown great promise in
current studies," stated Dr. Francisco
Marincola. "The unique and practical therapeutics in development by
Therapeutic Solutions International offer a fresh approach to
current immunotherapies and I am excited to participate in their
clinical translation."
Dr. Marincola
graduated summa cum laude at the University of Milan, Medical
School, Italy, and completed a general surgery residency with a
focus in immunology at Stanford University. He was president of the
Society for the Immunotherapy of Cancer and is the founding and
current editor-in-chief of the Journal of Translational
Medicine.
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION